Mode
Text Size
Log in / Sign up
Phase 2 Completed N=144 Randomized Quadruple-blind Treatment

Effectiveness of Bupropion for Treating Nicotine Dependence in Young People

Tobacco Use Cessation · Tobacco Use
Source: ClinicalTrials.gov NCT00129272 ↗
Enrolled (actual)
144
Serious AEs
0.0%
Results posted
Apr 2017
Primary outcomePrimary: Smoking Behavior — 6.4; 8.9 cigarettes/day in the previous week

Summary

Little is known about the best ways to help young people stop smoking. Bupropion (a medication marketed as Wellbutrin or Zyban) has proved helpful in treating adult smokers. The purpose of this study is to determine if bupropion is also effective in treating smokers between the ages of 12 and 25 years old. This study also compares the effectiveness of bupropion used as a supplement to behavioral treatment versus behavioral treatment used alone. In addition, the study evaluates whether hormonal response to stress measured prior to the start of treatment predicts whether individuals respond well to treatment with medication.

Outcome Measures

OutcomeResultp-value
PRIMARY
Smoking Behavior
6.4; 8.9
SECONDARY
Withdrawal Symptoms
2.5; 3.1

Eligibility Criteria

Inclusion Criteria

  • Has smoked at least 10 cigarettes each day for 3 or more months
  • Weighs at least 90 lbs
  • Motivated to quit smoking and has had at least one previous failed attempt
  • Speaks, reads, and writes English
  • Either diagnosed as depressed OR no history of a psychiatric disorder

Exclusion Criteria

  • History of bipolar disorder, eating disorder, schizophrenia, schizoaffective disorder, autism, or non-nicotine substance use disorder in the 6 months prior to study entry
  • Currently suicidal or with a history of a suicide attempt in the 6 months prior to study entry
  • Psychotic symptoms
  • Use of psychotropic medication(s)
  • Serious medical condition
  • Prior use of bupropion for smoking cessation
  • Currently using other smoking cessation treatments
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00129272). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search